Tissue Engineering Market (2025-2032)
The Tissue Engineering Market was valued at $1.91 billion in 2024. This market is expected to reach $7.41 billion by 2032 from an estimated $2.24 billion in 2025, at a CAGR of 18.6% during the forecast period of 2025-2032. Tissue Engineering Market Size & Forecast The growth of this market is driven
- Published
- Nov 2024
- Pages
- 187
- Format
- PDF + Excel
- Report ID
- MRHC - 1041406
- Base year
- 2024
- 2024 · BASELINE
- $1.91B
- 2032
- $7.41B
- CAGR 2025–2032
- 18.6%
2024 baseline · 2025–2032 forecast at 18.6% CAGR · hover a bar for the value
Key highlights
By Product: The scaffold Segment Dominates the Tissue Engineering Market in 2025
By Application: The Musculoskeletal & Orthopedics Segment to Dominate the Tissue Engineering Market in 2025
By End User: The Hospitals & Clinics Segment is Expected to Dominate the Tissue Engineering Market in 2025
By Geography: North America to Dominate the Tissue Engineering Market in 2025
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 187 |
| Format | |
| Forecast Period | 2025–2032 |
| Base Year | 2024 |
| CAGR (Value) | 18.6% |
| Market Size (Value) | USD 7.41 Billion by 2032 |
| Segments Covered | By Product · Scaffold · Biologically Derived Material · Collagen · Hydrogel · Stem Cells · Other biologically Derived Materials · Synthetic Material · Poly (propylene fumarate) (PPF) · Polylactic acid (PLA) · Poly (glycolic acid) (PGA) · Polycaprolactone (PCL) · Other Synthetic Materials · (Note 1: other biologically derived material includes chitosan, fibrinogen, and hyaluronan. · Note 2: Other synthetic materials include Polymethyl Methacrylate (PMMA) and poly(lactic-co-glycolic) acid (PLGA)) · Tissue Grafts · Allograft · Autograft · Synthetic Grafts · Xenograft · By Application · Musculoskeletal & Orthopedics · Oncology · Immunology and Inflammation · Neurology · Dermatology · Cardiology · Other Applications · (Note: other applications include wound care, urology, and gynecology) · By End User · Hospitals and Clinics · Ambulatory Surgical Centers |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Sweden, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa |
| Key Companies | Smith & Nephew plc (U.K.), Integra LifeSciences Holdings Corporation (U.S.), AbbVie Inc. (U.S.), Medtronic plc (Ireland), Zimmer Biomet Holdings, Inc. (U.S.), Organogenesis Inc. (U.S.), Becton, Dickinson and Company (C. R. Bard) (U.S.), Baxter International Inc. (U.S.), Octane Medical Group (Canada), Tissue Regenix Group plc (U.K.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.) |
Report overview
Segments covered: product, scaffold, biologically derived material, collagen, hydrogel, stem cell, other biologically derived material, synthetic material, other synthetic material, tissue graft, allograft, autograft, synthetic graft, xenograft, application, musculoskeletal & orthopedic, oncology, immunology, inflammation, neurology, dermatology, cardiology, other application, end user, hospital, clinic, ambulatory surgical center. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is driven by the rising approvals for tissue engineering products, rising demand for regenerative medicine, availability of funding for the development of tissue engineering products, and rising incidences of musculoskeletal disorders. Furthermore, advancements in tissue engineering products, the use of tissue engineering products in sports medicine, and the increasing application of tissue engineering products in newer therapy areas are expected to generate growth opportunities for the stakeholders in this market.
Report infographic
Market dynamics
4 factors across 3 forcesRising Approvals for Tissue Engineering Products
Tissue engineering leverages the body's natural healing mechanisms to repair, restore, or regenerate damaged or diseased tissues. The field has gained significant momentum in recent years, fueled by its promising applications across oncology, cardiology, neurology, and other medical specialties. Regulatory agencies, such as the FDA and EMA, are increasingly acknowledging the potential of regenerative therapies, including tissue engineering, to address critical unmet medical needs. This recognition is facilitating the market entry of innovative treatments, offering patients advanced solutions for a range of conditions. With the implementation of streamlined regulatory pathways, such as accelerated approval processes and orphan drug designations, approval timelines for tissue engineering products have been notably shortened, encouraging further research and investment in the field. As tissue engineering's applications expand across various therapeutic areas, regulatory bodies are progressively granting approvals for these products. Some of the recent approvals for tissue engineering products include:
-
In May 2025, Medtronic plc (Ireland) received FDA Breakthrough Device Designation for its Infuse bone graft with intervertebral fusion device. This expands its product portfolio in the cranial and spinal technologies segment.
- In April 2025, Abbott Laboratories (U.S.) received regulatory approval for the verolimus-eluting bioresorbable scaffold (Esprit BTK) for the treatment of patients with below-the-knee (BTK) infrapopliteal disease.
- In June 2024, the Indian Drugs Controller approved an animal-derived tissue engineering scaffold for healing skin wounds with minimum scarring. The tissue engineering scaffold is made up of mammalian organs called Cholederm.
Table of contents
11 chapters · 136 sections · 187 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Application | Musculoskeletal & Orthopedics | — |
By Application
- The musculoskeletal & orthopedics segment is estimated to account for the largest share of the tissue engineering market.
- The largest share of the segment can be attributed to the rising prevalence of musculoskeletal disorders, the growing demand for bone tissue engineering, and the increasing incidence of road accidents.
- In the event of road accidents, tissue engineering products play a critical role in reconstructing and repairing damaged tissues.
- Additionally, orthopedic surgeons are increasingly using tissue engineering as a therapeutic option for treating a variety of musculoskeletal lesions, from meniscal deficiencies in young athletes to osteochondral defects in the glenohumeral joint.
- The rising incidence of sports-related injuries is further driving the demand for tissue engineering products.
- According to the Centers for Disease Control and Prevention (CDC), more than 3.5 million sports injuries occur annually in the U.S., highlighting the growing need for advanced treatment solutions in this area.
Geographic analysis
North America
Largest shareIn 2025, North America is estimated to account for the largest share of the tissue engineering market. The dominant share of this regional market is driven by several factors, including the rising prevalence of chronic conditions such as cancer, neurological disorders, and cardiovascular diseases, as well as increased funding for tissue engineering development. The presence of leading tissue engineering manufacturers in the region, growing awareness of the benefits of tissue engineering, and the active involvement of academic and research institutions in advanced R&D also contribute to market growth. Additionally, strong support from government bodies and regulatory authorities is promoting the adoption of tissue engineering products for medical applications. Both public and private organizations in the region are providing critical funding to advance tissue engineering innovation. For example, in July 2025, the Canadian government allocated USD 22.5 million to STEMCELL Technologies for the development of a state-of-the-art facility in Burnaby, British Columbia. This facility is designed to support the manufacturing and clinical trials of cell therapy, gene therapy, tissue engineering, and immunotherapy to address various chronic and degenerative conditions. North America Dominates the Tissue Engineering Market in 2025
Asia-Pacific
Fastest growthHowever, Asia-Pacific is slated to register the highest CAGR during the forecast period. Asia-Pacific is emerging as one of the fastest-growing markets for tissue engineering, fueled by increasing healthcare expenditures, a rapidly aging population, and a rising incidence of target diseases. Furthermore, the region is witnessing a surge in conferences dedicated to advancing tissue engineering and robust research initiatives, which are expected to significantly enhance awareness and drive broader adoption of these therapies.
Competitive landscape
- March 2025
HVD Life Science Vertriebs-GmbH (Austria) partnered with Poietis (France) for the distribution of the NGB-RTM Bioprinting platform in Austria and Germany. This collaboration brings cutting-edge bioprinting technology to the forefront of R&D in tissue engineering and regenerative medicine.
- October 2024
Smith & Nephew plc (U.K.) launched the REGENETEN Bioinductive Implant in Japan. This wound care patch supports new tendon-like tissue growth and initiates biological tendon regeneration.
- May 2022
Darling International Inc. (U.S.) health brand Rousselot launched a Quali-Pure HGP 2000, a new pharmaceutical-grade, endotoxin-controlled gelatin specifically designed for vaccines and wound healing applications.
- February 2022
Orthofix Medical Inc. (U.S.) launched an Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures.
- Smith & Nephew plc (U.K.)
- Integra LifeSciences Holdings Corporation (U.S.)
- AbbVie Inc. (U.S.)
- Medtronic plc · Ireland
- Zimmer Biomet Holdings, Inc. (U.S.)
- Organogenesis Inc. (U.S.)
- Becton
- Dickinson and Company (C. R. Bard) (U.S.)
- Baxter International Inc. (U.S.)
- Octane Medical Group · Canada
- Tissue Regenix Group plc (U.K.)
- Stryker Corporation (U.S.)
- NuVasive, Inc. (U.S.)
Frequently asked questions
The tissue engineering market size was valued at $1.91 billion in 2024.
Cite this report
Meticulous Research. (2024). Tissue Engineering Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041406). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/tissue-engineering-market-6089